natgillin/translations-raw huggingface dataset:
0.5 ml concentrate for solution for infusion in a pre-filled syringe (type I glass, siliconised) with plunger stopper (bromobutyl rubber) and luer lock system (polypropylene siliconised and polycarbonate) with tip cap (styrene butadiene rubber) with a cannula; pack size of 1. 
0,5 ml koncentrata za otopinu za infuziju u napunjenoj štrcaljki (staklo tip I, silikonizirano) s čepom klipa (bromobutil guma) i luer lock sustavom (silikonizirani polipropilen i polikarbonat) sa zatvaračem vrha (stiren butadien guma) s cjevčicom; veličina pakiranja: 1. 6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom
Diluted Removab. 
(Dio vanjskog pakiranja) Razrijeđeni Removab.
In Table 1, adverse reactions are listed by organ class. 
U Tablici 1 nuspojave su navedene po organskim sustavima.
Dyspnoea and hypo-/ hypertension are commonly observed. 
Dispneja te hipo/hipertenzija bili su česti.
What Removab looks like and contents of the pack Removab is presented as a clear and colourless concentrate for solution for infusion in a pre-filled syringe with a cannula. 
Removab je bistri i bezbojni koncentrat za otopinu za infuziju u napunjenoj štrcaljki s cjevčicom.
• polyurethane, polyurethane silicon coated catheters 
• poliuretanom, poliuretanskim kateterima obloženim silikonom Uz to, potrebno je sljedeće:
Catumaxomab was administered as four intraperitoneal infusions with increased doses of 10, 20, 50 and 150 micrograms on day 0, 3, 7 and 10, respectively (see section 4.2). 
Katumaksomab je primijenjen u četiri intraperitonealne infuzije s povećanjem doza od 10, 20, 50 i 150 mikrograma na dan 0, 3, 7 i 10 (vidjeti dio 4.2).
50 micrograms on day 7 
3. doza 50 mikrograma 7. dan
Hepatic impairment or portal vein thrombosis / obstruction Patients with hepatic impairment of a higher severity grade than moderate and / or with more than 70% of the liver metastasised and / or portal vein thrombosis / obstruction have not been investigated. 
U ispitivanja nisu uključivani bolesnici s oštećenjem funkcije jetre većeg stupnja od umjerenog i/ili s više od 70% tkiva jetre zahvaćenog metastazama i/ili trombozom/opstrukcijom portalne vene.
10 micrograms pre-filled syringe 
10 mikrograma napunjena štrcaljka
Patients with renal impairment of a higher severity grade than mild have not been investigated. 
U ispitivanja nisu uključivani bolesnici s oštećenjem funkcije bubrega većim od blagog.
Headache, dizziness. 
Glavobolja, vrtoglavica
Total volume of Removab concentrate for solution for infusion 
Ukupan volumen Removab koncentrata za otopinu za infuziju
oedema peripheral*, general physical health deterioration*, chest pain, influenza-like illness, malaise*, catheter site erythema. 
Bol, astenija*, sindrom sistemskog upalnog odgovora*, edem uključujući periferni edem*, opće fizičko pogoršanje zdravlja*, bol u prsima, bolest slična gripi, slabost*, eritem na mjestu katetera
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister: Removab 10 micrograms 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Blister: Removab 10 mikrograma
150 micrograms on day 10 
4. doza 150 mikrograma 10. dan
50 micrograms pre-filled syringe 
50 mikrograma napunjena štrcaljka
Median puncture-free survival (days) 95% CI for median (days) p-value (log-rank test) 
Medijan preživljenja bez punkcije (dani) 95% CI za medijan (dani) p-vrijednost (log-rank test)
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister: Removab 50 micrograms 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Blister: Removab 50 mikrograma
• The pre-filled syringe cannula is inserted through the 50 ml syringe opening so that the cannula is immersed in the sodium chloride 9 mg/ml (0.9%) solution for injection (Figure 2). 
• Cjevčica napunjene štrcaljke umetne se kroz otvor štrcaljke od 50 ml tako da je cjevčica uronjena u 9 mg/ml (0,9%) otopinu natrijevog klorida za injekciju (Slika 2).
Sodium chloride 9 mg/ml (0.9%) solution for injection 
Natrijev klorid 9 mg/ml (0,9%) otopina za injekciju
Respiratory, thoracic and mediastinal disorders Common 
Poremećaji dišnog sustava, prsišta i sredoprsja
Removab dosing schedule comprises the following four intraperitoneal infusions: 1st dose 
Četiri infuzije Removaba za intraperitonealnu primjenu doziraju se na sljedeći način: 1. doza 10 mikrograma 0. dan
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton: Removab 50 micrograms 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija: Removab 50 mikrograma
Removab must not be administered as a bolus or by any route other than intraperitoneally. 
Removab se ne smije primjenjivati u obliku bolusa ili nekim drugim načinom primjene osim u trbušnu šupljinu.
gastric disorder, ileus*, gastroesophageal reflux disease, dry mouth. 
flatulencija, želučani poremećaji, ileus *, gastroezofagealna refluksna bolest,
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton: Removab 10 micrograms 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija: Removab 10 mikrograma
Hypotension*, hypertension*, flushing. 
Hipotenzija*, hipertenzija*, crvenilo uz osjećaj vrućine
A pivotal, two-arm, randomised, open-label, phase II/III clinical trial in 258 patients with symptomatic malignant ascites due to EpCAM-positive carcinomas of whom 170 were randomised to catumaxomab treatment. 
Pivotalno, randomizirano, otvoreno kliničko ispitivanje u fazama II/III s dvije skupine ispitanika obuhvatilo je 258 bolesnika sa simptomatskim malignim ascitesom uzrokovanim
50 ml Syringe 
štrcaljka od 50 ml
3rd infusion 50 micrograms 
3. infuzija 50 mikrograma
Median overall survival (days) 95% CI for median (days) p-value (log-rank test) Hazard ratio (HR) (Catumaxomab versus Catumaxomab + Prednisolone) 95% CI for HR 
95% CI za medijan (dani) p-vrijednost (log-rank test) Omjer hazarda (HR) (katumaksomab naspram katumaksomab + prednizolon) 95% CI za HR
• The enclosed cannula is attached to the Removab pre-filled syringe. 
• Priložena se cjevčica pričvrsti na Removab napunjenu štrcaljku.
Common serious side effects (may affect up to 1 in 10 people): - Loss of appetite - Dehydration - Reduction in red blood cells (anaemia) - Decreased blood levels of calcium and sodium - A very fast heart beat - High or low blood pressure - Abdominal pain accompanied by difficulty or blockage passing stools, constipation - Shortness of breath - Accumulation of fluid around the lungs which cause chest pain and breathlessness - Inflammation of the bile ducts - Skin redness, rash - Very fast heartbeat, fever, shortness of breath, feeling faint or light-headed - Complex of reactions due to the release of mediators of inflammation - Worsening of general state of health, generally feeling unwell and weak - Fluid retention - Hypersensitivity 
Česte ozbiljne nuspojave (mogu se javiti u do 1 na 10 osoba): - Gubitak apetita - Dehidracija - Smanjenje broja crvenih krvnih stanica (anemija) - Smanjene razine kalcija i natrija u krvi - Ubrzani rad srca - Visoki ili niski krvni tlak - Bolovi u trbuhu popraćeni poteškoćama ili blokadom prolaska stolice, zatvor - Nedostatak zraka
Very common Abdominal pain*, nausea*, vomiting*, diarrhoea*. 
Bol u trbuhu*, mučnina*, povraćanje*, proljev*
infusion cycle consisting of 10, 20, 50 and 150 micrograms of catumaxomab in 8 patients with malignant ascites due to carcinoma (IP-CAT-AC-04) 
U ispitivanju izvedivosti kojim je procjenjivan drugi ciklus i.p. infuzija koji se sastojao od 10, 20, 50 i 150 mikrograma katumaksomaba u 8 bolesnika s malignim ascitesom zbog karcinoma (IP-CAT-AC04) adenozin deaminaza (ADA) bila je detektibilna u svim dostupnim uzorcima ascitesa i plazme pri probiru.
Uncommon Gastrointestinal haemorrhage*, intestinal obstruction*. 
Manje često Gastrointestinalno krvarenje*, crijevna opstrukcija*
sinus tachycardia. 
Tahikardija*, uključujući sinus tahikardiju
Uncommon Extravasation*, application site inflammation*. 
Manje često Ekstravazacija*, upala na mjestu primjene*
Anaemia*, lymphopenia, leukocytosis, neutrophilia. 
Anemija*, limfopenija, leukocitoza, neutrofilija Manje često Trombocitopenija*, koagulopatija*
It is important to tell your doctor if you have any of the following: - undrained fluid in your abdominal cavity - cold hands and feet, light headedness, difficulty passing urine, increased heart rate, and weakness (symptoms of low blood volume) - weight gain, weakness, shortness of breath and fluid retention (symptoms of low blood protein levels) - feeling dizzy and faint (symptoms of low blood pressure) - problems with your heart and circulation - kidney or liver problems - an infection. 
Važno je da obavijestite svog liječnika ako se na Vas odnosi nešto od sljedećeg: - imate nakupljenu tekućinu u trbušnoj šupljini - imate hladne ruke ili noge, blagu ošamućenost, poteškoće s mokrenjem, ubrzani rad srca,
Table 2 EpCAM expression in most relevant ascites causing cancer types 
Tablica 2 Izraženost EpCAM antigena pri sijelima raka koji uzrokuju stvaranje ascitesa Retrospektivni podaci iz ispitivanja
Removab must be administered under the supervision of a physician experienced in the use of anti-neoplastic medicinal products. 
4.2 Doziranje i način primjene Removab se mora primjenjivati pod nadzorom liječnika s iskustvom u primjeni antineoplastičnih lijekova.
The catheter for intraperitoneal administration should be placed under ultrasound guidance by a physician experienced in intraperitoneal administration procedures. 
Kateter za primjenu u trbušnu šupljinu trebao bi pod kontrolom ultrazvuka uvesti liječnik s iskustvom u postupku primjene lijeka u trbušnu šupljinu.
Hepatic impairment 
- Osjećaj vrtoglavice
Ear and labyrinth disorders Common 
Manje često Konvulzije* Poremećaji uha i labirinta Često
Hazard ratio (HR) 
Omjer hazarda (HR) (katumaksomab naspram katumaksomab + prednizolon)
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-filled syringe: Removab 50 micrograms 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE Napunjena štrcaljka: Removab 50 mikrograma
Ascites drainage 
Evakuacija ascitesa
One pre-filled syringe contains 50 micrograms catumaxomab in 0.5 ml solution, corresponding to 0.1 mg/ml. 
Jedna napunjena štrcaljka sadrži 50 mikrograma katumaksomaba u 0,5 ml otopine, što odgovara 0,1 mg/ml.
One pre-filled syringe contains 10 micrograms catumaxomab in 0.1 ml solution, corresponding to 0.1 mg/ml. 
Jedna napunjena štrcaljka sadrži 10 mikrograma katumaksomaba u 0,1 ml otopine, što odgovara 0,1 mg/ml.
Constipation*, dyspepsia, abdominal distension, sub-ileus*, flatulence, 
Konstipacija*, dispepsija, bolovi zbog rastezanja trbušne stijenke, subileus*,
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-filled syringe: Removab 10 micrograms 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE Napunjena štrcaljka: Removab 10 mikrograma
Time to first need for therapeutic ascites puncture Median time to first need for therapeutic ascites puncture (days) 
Vrijeme do prve potrebne terapijske punkcije ascitesa
Number of Removab pre-filled syringe(s) 
Broj Removab napunjenih štrcaljki
EXP 
antigen
infusions in doses of 10, 20, 50 and 150 micrograms on day 0, 3, 7 and 10, respectively, in both groups. 
Katumaksomab je primjenjen u četiri 3-satne i.p. infuzije konstantne brzine u dozama od 10, 20, 50 i 150 mikrograma na dan 0, 3, 7 i 10, kod obje skupine ispitanika.
Intraperitoneal use only.” must be attached to the 50 ml syringe containing the diluted Removab solution for intraperitoneal infusion. 
mora se pričvrstiti na štrcaljku od 50 ml koja sadrži razrijeđenu otopinu Removaba za primjenu u trbušnu šupljinu.
Removab 10 micrograms concentrate for solution for infusion catumaxomab 
Removab 10 mikrograma koncentrat za otopinu za infuziju katumaksomab
Removab 50 micrograms concentrate for solution for infusion catumaxomab 
Removab 50 mikrograma koncentrat za otopinu za infuziju katumaksomab
Am Haag 6-7 
Am Haag 6-7 82166 Graefelfing
Uncommon serious side effects (may affect up to 1 in 100 people): - Lumps under the skin on the back of the legs that may become sores and leave scars - Inflammation and pain or burning and stinging in the area around the catheter - Reduction in number of blood platelets, blood clotting problems - Bleeding in the stomach or gut, shown by the vomiting of blood or the passage of red or black stools - Skin reaction, severe allergic skin reaction (dermatitis) - Fits - Lung problems including blood clot in the lungs - Low blood oxygen levels - Severe kidney problems - Extravasation (inadvertent leakage of administered medicinal product from the intraperitoneal catheter system into surrounding tissue) 
- Smanjenje broja trombocita, problemi sa zgrušavanjem krvi - Krvarenje u želucu ili crijevima, koje se očituje povraćanjem krvi ili crvenom ili crnom stolicom - Kožna reakcija, teška alergijska kožna reakcija (dermatitis) - Napadaji
Hazard ratio (HR) (Catumaxomab versus Catumaxomab + Prednisolone) 95% CI for HR 
Omjer hazarda (HR) 95% CI za HR
What Removab contains - The active substance is catumaxomab (50 micrograms in 0.5 ml, corresponding to 0.1 mg/ml). 
- Djelatna tvar je katumaksomab (50 mikrograma u 0,5 ml, što odgovara 0,1 mg/ml).
What Removab contains - The active substance is catumaxomab (10 micrograms in 0.1 ml, corresponding to 0.1 mg/ml). 
- Djelatna tvar je katumaksomab (10 mikrograma u 0,1 ml, što odgovara 0,1 mg/ml).
Intraperitoneal use only, after dilution. 
Samo za primjenu u trbušnu šupljinu, nakon razrjeđivanja.
Posology 
Katumaksomab
In one patient (0.1%) dyspnoea and in 3 patients (0.4%) hypotension was reported in CTCAE grade 4 intensity. 
Dispneja u jednog bolesnika (0,1%) i hipotenzija u 3 bolesnika (0,4%) prijavljeni su s intenzitetom CTCAE stupnja 4. Simptomi boli i pireksije mogu se ublažiti ili izbjeći premedikacijom (vidjeti dio 4.2 i 4.4).
Patients of nonCaucasian origin have not been included in these clinical studies. 
U ova klinička ispitivanja nisu bili uključeni drugi bolesnici osim bolesnika bijele rase.
Precautions to be taken before administering the medicinal product Before administration of Removab the concentrate for solution for infusion is diluted in sodium chloride 9 mg/ml (0.9%) solution for injection. 
Prije primjene Removaba koncentrat za otopinu za infuziju potrebno je razrijediti u 9 mg/ml (0,9%) otopini natrijevog klorida za injekciju.
(Part of the Outer Carton) 
(Tablica 4).
Proteinuria. 
Gušterača
Common side effects (may affect up to 1 in 10 people): - Pain - Reduction or increase in number of white blood cells - Decreased blood levels of potassium - Decreased blood protein levels - Increase of bilirubin in blood - Spinning sensation - Indigestion, stomach problems, heartburn, feeling bloated, passing wind, dry mouth - Flu-like symptoms - Dizziness or headache - Chest pain - Increased sweating - Infections - Increased protein levels in urine - Back pain, aching muscles and joints - Feeling anxious and having difficulty sleeping - Itchy rash or hives - Redness of the skin in the area around the catheter - Flushing - Cough 
- Povećane razine proteina u urinu - Bol u leđima, bol u mišićima i zglobovima - Osjećaj tjeskobe i poteškoće sa spavanjem - Osip koji svrbi ili koprivnjača - Crvenilo kože u području oko katetera
3 Perfusion Tubing (1 mm inner diameter, 150 cm length) 5 Perfusion Lead 
1 250 ml natrijevog klorida 9 mg/ml (0,9%) 2 Removab otopina za i.p. infuziju 3 Perfuzijske cijevi (1 mm unutrašnji promjer, 150 cm dužina) 4 Infuzijski ventil
• Sodium chloride 9 mg/ml (0.9%) solution for injection 
• 9 mg/ml (0,9%) otopina natrijevog klorida za injekciju • precizna perfuzijska pumpa
• The tip cap from the Removab pre-filled syringe is removed with the tip pointing up. 
• Ukloni se zatvarač vrha s Removab napunjene štrcaljke pri čemu ona mora biti usmjerena vrhom prema gore.
Uncommon Renal failure acute*. 
Proteinurija Manje često Akutno zatajenje bubrega*
What Removab is and what it is used for What you need to know before you use Removab How to use Removab 
Što morate znati pije nego počnete primjenjivati Removab
Abdominal pain 
Sijelo antigen
Gastric 
prednizolon
Sodium citrate Citric acid monohydrate Polysorbate 80 
FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari natrijev citrat citratna kiselina hidrat polisorbat 80 voda za injekcije
QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled syringe contains 10 micrograms of catumaxomab* in 0.1 ml solution, corresponding to 0.1 mg/ml. 
Jedna napunjena štrcaljka sadrži 10 mikrograma katumaksomaba* u 0,1 ml otopine, što odgovara 0,1 mg/ml.
QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled syringe contains 50 micrograms of catumaxomab* in 0.5 ml solution, corresponding to 0.1 mg/ml. 
Jedna napunjena štrcaljka sadrži 50 mikrograma katumaksomaba* u 0,5 ml otopine, što odgovara 0,1 mg/ml.
Ovarian 
Jajnik
Subsequently, prior to each Removab administration 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection shall be infused to support distribution of the antibody in the abdominal cavity. 
ml otopine natrijevog klorida 9 mg/ml (0,9%) za injekciju kako bi se pospješila raspodjela protutijela u trbušnoj šupljini.
Cancer Type 
NAZIV LIJEKA
NAME OF THE MEDICINAL PRODUCT Removab 50 micrograms concentrate for solution for infusion 
Removab 50 mikrograma koncentrat za otopinu za infuziju
NAME OF THE MEDICINAL PRODUCT Removab 10 micrograms concentrate for solution for infusion 
Removab 10 mikrograma koncentrat za otopinu za infuziju
National or local guidance should be taken into consideration. 
U obzir treba uzeti nacionalne ili lokalne smjernice.
If you miss an injection, you should have it as soon as possible. 
Ako propustite injekciju, morate je primiti što je prije moguće.
Do not stop taking Rocephin unless your doctor tells you to. 
Nemojte prestati primati Rocephin, osim ako Vam tako ne kaže liječnik.
Rocephin is usually given by a doctor or nurse. 
Rocephin obično daje liječnik ili medicinska sestra.
However, if it is almost time for your next injection, skip the missed injection. 
Međutim, ako je uskoro vrijeme za sljedeću injekciju, preskočite propuštenu injekciju.
Talk to your doctor if you experience these symptoms. 
Obratite se svom liječniku ako primijetite bilo koji od tih simptoma.
The incidence appears to be lower with slow infusion (20 - 30 minutes). 
Čini se da je incidencija manja kod sporije infuzije (20-30 minuta).
There is no specific antidote. 
Nema specifičnog protulijeka.
The signs may include: 
Znakovi mogu uključivati:
The duration of therapy varies according to the course of the disease. 
Trajanje terapije varira ovisno o tijeku bolesti.
Acute otitis media 
Akutni otitis media
The number of days or weeks that you are given Rocephin depends on what sort of infection you have. 
Broj dana ili tjedana tijekom kojih ćete primati Rocephin ovisi o vrsti infekcije koju imate.
Package leaflet: Information for the Patient 
Uputa o lijeku: Informacija za bolesnika
Treatment of overdose should be symptomatic. 
Liječenje predoziranja treba biti simptomatsko.
Do not take a double dose (two injections at the same time) to make up for a missed dose. 
Nemojte primiti dvostruku dozu (dvije injekcije odjednom) kako biste nadoknadili propuštenu dozu.
Patients should be cautious when driving or operating machinery. 
Bolesnici moraju biti oprezni kada upravljaju vozilom ili rade sa strojevima.
You may be given a different dose to the usual dose. 
Možda ćete primiti dozu drugačiju od uobičajene.
In older people aged over 75 years the average elimination half-life is usually two to three times that of young adults. 
U starijih osoba u dobi iznad 75 godina prosječan poluvijek eliminacije obično je dvostruko ili trostruko dulji nego u mladih odraslih osoba.
• Blood or sugar in your urine. 
• krv ili šećer u mokraći
If you feel dizzy, do not drive or use any tools or machines. 
Ako osjetite omaglicu, nemojte voziti niti rukovati alatima i strojevima.
The risk of precipitate formation is increased in immobilized or dehydrated patients. 
Rizik od nastanka precipitata povećan je u imobiliziranih ili dehidriranih bolesnika.
The doses recommended in the tables below are the generally recommended doses in these indications. 
Doze preporučene u sljedećim tablicama su doze koje se općenito preporučuju u navedenim indikacijama.
The possibility of sensitisation should be taken into account. 
U obzir treba uzeti i mogućnost senzitizacije.
During childhood, the half-life is lower than in neonates or adults. 
U djetinjstvu je poluvijek kraći nego u novorođenčadi ili odraslih.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. 
Za uputu o rekonstituciji lijeka prije primjene, vidjeti dio 6.6.
If you need a blood or urine test 
Ako morate obaviti pretrage krvi ili mokraće
Your doctor will decide the correct dose of Rocephin for you. 
Liječnik će odrediti točnu dozu lijeka Rocephin za Vas.
• The baby is premature. 
• ako je rođeno prerano
Penetration is greatest when the meninges are inflamed. 
Penetracija je najveća kada su moždane ovojnice upaljene.
Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms: 
Rezistencija bakterija na ceftriakson može biti posljedica jednoga ili više sljedećih mehanizama:
Consideration should be given to official guidelines on the appropriate use of antibacterial agents. 
Treba uzeti u obzir službene preporuke o primjerenoj uporabi antibiotika.
If you are given Rocephin for a long time, you may need to have regular blood tests. 
Ako dugotrajno primate Rocephin, možda ćete redovito morati obavljati krvne pretrage.
Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known. 
Budući da je te nuspojave dobrovoljno prijavila populacija neodređene veličine, nije moguće pouzdano odrediti njihovu učestalost, pa ih se stoga svrstava u kategoriju 'nepoznato'.
Newborn babies (0-14 days) 
Novorođenčad (0-14 dana)
• Rocephin may interfere with some types of blood glucose tests - please check with your doctor. 
• Rocephin može utjecati na neke vrste testova za utvrđivanje šećera u krvi - molimo provjerite sa svojim liječnikom.
Caution should be particularly considered in the paediatric population. 
Osobit oprez potreban je u pedijatrijskoj populaciji.
If you accidentally receive more than your prescribed dose, contact your doctor or nearest hospital straight away. 
Ako slučajno primite dozu veću od propisane, obratite se svom liječniku ili se odmah javite u najbližu bolnicu.
It works by killing bacteria that cause infections. 
Djeluje tako da uništava bakterije koje uzrokuju infekcije.
Inherently resistant organisms 
Inherentno rezistentni organizmi
In particular, tell your doctor or pharmacist if you are taking any of the following medicines: 
Osobito je važno da kažete liječniku ili ljekarniku ako uzimate neki od sljedećih lijekova:
The recommended treatment durations vary and national or local guidelines should be taken into consideration. 
Preporučeno trajanje liječenja je različito pa u obzir treba uzeti nacionalne ili lokalne smjernice.
the heart. 
• srca.
The elimination half-life of total ceftriaxone in adults is about 8 hours. 
Poluvrijeme eliminacije ukupnog ceftriaksona u odraslih iznosi približno 8 sati.
The doctor will consider the benefit of treating you with Rocephin against the risk to your baby. 
Liječnik će razmotriti koristi liječenja lijekom Rocephin za Vas u odnosu na rizike za Vaše dijete.
If you are given more Rocephin than you should 
Ako primite više lijeka Rocephin nego što ste trebali
Rocephin may be used: 
Rocephin se može koristiti:
Interaction with calcium containing products 
Interakcija s proizvodima koji sadrže kalcij
Commonly susceptible species 
Vrste koje su obično osjetljive
Other medicines and Rocephin 
Drugi lijekovi i Rocephin
• An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes). 
• antibiotik koji se zove kloramfenikol (koristi se za liječenje infekcija, osobito infekcija oka).
Symptomatic treatment is recommended in these cases. 
U tim se slučajevima preporučuje simptomatsko liječenje.
Gram-positive aerobes 
Gram-pozitivni aerobi